|
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse
|
Jul 2020
|
Blood Advances
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years
|
Oct 2019
|
Blood Advances
|
aplastic anemia
|
|
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
|
Mar 2017
|
Blood Advances
|
acute myeloid leukemia (AML)
|
|
DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes
|
Oct 2019
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia
|
Apr 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
|
Apr 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
|
Apr 2023
|
Blood Cancer
|
myelodysplastic syndromes (MDS)
|
|
Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes
|
Sep 2017
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
|
Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
|
Mar 2012
|
Blood Cancer J
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
|
Mar 2015
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
